康泰生物
(300601)
| 流通市值：114.98亿 | | | 总市值：142.63亿 |
| 流通股本：9.00亿 | | | 总股本：11.17亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 631,111,744.14 | 2,673,083,107.93 | 2,063,443,044.89 | 1,392,061,330.52 |
| 营业总成本 | 599,367,752.11 | 2,504,875,738.79 | 1,925,316,368.3 | 1,293,245,266.49 |
| 其他经营收益 | | | | |
| 营业利润 | 40,636,356.48 | 38,069,305.12 | 5,892,770.88 | 1,725,506.28 |
| 利润总额 | 39,948,409.67 | 45,464,124.47 | 202,302.43 | -121,922.01 |
| 净利润 | 33,600,071.1 | 70,273,947.22 | 49,182,357.58 | 37,600,910.41 |
| 每股收益 | | | | |
| 其他综合收益 | -35,940.55 | -115,810.65 | -93,372.99 | -95,966.13 |
| 综合收益总额 | 33,564,130.55 | 70,158,136.57 | 49,088,984.59 | 37,504,944.28 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 5,956,587,525.96 | 5,994,731,385.56 | 6,212,566,030.99 | 6,091,018,947.57 |
| 非流动资产: | | | | |
| 非流动资产合计 | 8,029,828,631.35 | 8,100,687,031.3 | 7,921,760,489.29 | 8,037,905,855.32 |
| 资产总计 | 13,986,416,157.31 | 14,095,418,416.86 | 14,134,326,520.28 | 14,128,924,802.89 |
| 流动负债: | | | | |
| 流动负债合计 | 2,074,853,594.75 | 2,215,684,335.34 | 2,300,430,568.07 | 2,287,083,688.21 |
| 非流动负债: | | | | |
| 非流动负债合计 | 2,246,404,590.73 | 2,248,145,880.01 | 2,223,380,772.98 | 2,242,918,295.63 |
| 负债合计 | 4,321,258,185.48 | 4,463,830,215.35 | 4,523,811,341.05 | 4,530,001,983.84 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 9,665,052,013.2 | 9,631,743,291.33 | 9,610,589,069.34 | 9,598,953,225.9 |
| 股东权益合计 | 9,665,157,971.83 | 9,631,588,201.51 | 9,610,515,179.23 | 9,598,922,819.05 |
| 负债和股东权益合计 | 13,986,416,157.31 | 14,095,418,416.86 | 14,134,326,520.28 | 14,128,924,802.89 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 541,946,587.85 | 2,993,877,739.25 | 2,054,617,371.98 | 1,283,499,324.32 |
| 经营活动现金流出小计 | 641,222,486.18 | 2,358,308,453.89 | 1,692,154,072.25 | 1,207,902,571.92 |
| 经营活动产生的现金流量净额 | -99,275,898.33 | 635,569,285.36 | 362,463,299.73 | 75,596,752.4 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 636,751,308.45 | 4,398,711,211.98 | 2,244,103,059.45 | 867,721,438.36 |
| 投资活动现金流出小计 | 600,449,552.81 | 4,882,722,833.18 | 1,570,315,399.79 | 869,983,024.59 |
| 投资活动产生的现金流量净额 | 36,301,755.64 | -484,011,621.2 | 673,787,659.66 | -2,261,586.23 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 11,000,000 | 51,665,606.11 | 51,665,606.11 | 39,984,357.78 |
| 筹资活动现金流出小计 | 120,604.5 | 396,473,821.72 | 381,933,620.34 | 326,019,151.68 |
| 筹资活动产生的现金流量净额 | 10,879,395.5 | -344,808,215.61 | -330,268,014.23 | -286,034,793.9 |
| 汇率变动对现金及现金等价物的影响 | -1,325,405.62 | -959,185.16 | -380,193.69 | -205,643.66 |
| 现金及现金等价物净增加额 | -53,420,152.81 | -194,209,736.61 | 705,602,751.47 | -212,905,271.39 |
| 期末现金及现金等价物余额 | 168,439,365.03 | 221,859,517.84 | 1,121,672,005.92 | 203,163,983.06 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -194,209,736.61 | - | -212,905,271.39 |